Drug · CHEMBL573
NIACIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. NIACIN. Drugs and targets, record CHEMBL573. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL573
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Niacin component of advicor, Niacin component of simcor, Niacin td, Niacor, Niaspan, Niaspan er, Niaspan titration starter pack, Nicangin, Nicolar, Wampocap
- ChEMBL
- Other names
- Acide nicotinique, Acido nicotinico, Acidum nicotinicum, NSC-169454, Niacin extended release, Nicotinate, Nicotinic acid, Vitamin b3
- ChEMBL
- Open Targets' highest stage
- Approval, for 12 of its 52 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases52
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 52Source Open Targets
See all 52 diseasesTrials154
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00461630 | Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE | Phase 3 | 25,673 | 2014-01-28 | niacin | Its name | ClinicalTrials.gov |
| NCT00120289 | Niacin Plus Statin to Prevent Vascular Events | Phase 3 | 3,414 | 2015-06-17 | niacin | Its name | ClinicalTrials.gov |
| NCT00289900 | Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) | Phase 3 | 2,340 | 2016-01-26 | MK-0524A, niacin | Its name | ClinicalTrials.gov |
| NCT00271817 | To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED) | Phase 3 | 1,220 | 2009-08-03 | niacin | Its name | ClinicalTrials.gov |
| NCT00479388 | Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) | Phase 3 | 1,216 | 2009-07-31 | niacin | Its name | ClinicalTrials.gov |
| NCT01274559 | Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) | Phase 3 | 1,173 | 2014-03-14 | niacin | Its name | ClinicalTrials.gov |
| NCT00961636 | A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) | Phase 3 | 1,152 | 2012-02-17 | niacin | Its name | ClinicalTrials.gov |
| NCT01335997 | Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) | Phase 3 | 1,139 | 2016-06-21 | niacin | Its name | ClinicalTrials.gov |
| NCT01294683 | A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) | Phase 3 | 977 | 2016-12-13 | niacin | Its name | ClinicalTrials.gov |
| NCT00384293 | Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) | Phase 3 | 937 | 2009-09-02 | niacin | Its name | ClinicalTrials.gov |
1 to 10 of 154
See all 154 trialsComparisons in its trials37
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ER Niacin/Laropiprant vs Placebo: Major Vascular Event | 1,696 of 12,838 | 1,758 of 12,835 | 25,673 | NCT00461630 | Trial comparisons |
| ER Niacin/Laropiprant vs Placebo: Mortality | 798 of 12,838 | 732 of 12,835 | 25,673 | NCT00461630 | Trial comparisons |
| ER Niacin/Laropiprant vs Placebo: Major Coronary Events | 668 of 12,838 | 694 of 12,835 | 25,673 | NCT00461630 | Trial comparisons |
| ER Niacin/Laropiprant vs Placebo: Stroke | 498 of 12,838 | 499 of 12,835 | 25,673 | NCT00461630 | Trial comparisons |
| ER Niacin/Laropiprant vs Placebo: Coronary or Non-coronary Revascularisation | 807 of 12,838 | 897 of 12,835 | 25,673 | NCT00461630 | Trial comparisons |
| ER Niacin/Laropiprant vs Placebo: serious adverse events | 7,137 of 12,838 | 6,762 of 12,835 | 25,673 | NCT00461630 | Trial comparisons |
ERN + Simvastatin vs Placebo + Simvastatin: Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization | 282 of 1,718 | 274 of 1,696 | 3,414 | NCT00120289 | Trial comparisons |
| ERN + Simvastatin vs Placebo + Simvastatin: Cardiovascular Mortality | 45 of 1,718 | 38 of 1,696 | 3,414 | NCT00120289 | Trial comparisons |
| ERN + Simvastatin vs Placebo + Simvastatin: Composite Endpoint of CHD Death, Non-fatal MI, High-risk ACS or Ischemic Stroke | 171 of 1,718 | 158 of 1,696 | 3,414 | NCT00120289 | Trial comparisons |
| ERN + Simvastatin vs Placebo + Simvastatin: Composite Endpoint of CHD Death, Non-fatal MI, or Ischemic Stroke | 156 of 1,718 | 138 of 1,696 | 3,414 | NCT00120289 | Trial comparisons |
1 to 10 of 37
See all 37 comparisons in its trialsPapers from its trials110
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Multi-Source Interference Task | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL573
GET https://conductscience.org/api/drugs/v1/CHEMBL573/diseases?page=2